Xpeng Stock Soars on Iron Robot & 2026 Robotaxi Plans
Xpeng shares surged after unveiling its next-gen 'Iron' humanoid robot and plans for three AI robotaxi models in 2026.
Already have an account? Sign in.
Xpeng shares surged after unveiling its next-gen 'Iron' humanoid robot and plans for three AI robotaxi models in 2026.
Goldman Sachs upgraded Arcus Biosciences to Buy, raising its price target to $28 on promising results for its lead cancer drug Casdatifan.
Solid Biosciences receives FDA Orphan Drug designation for SGT-212, a dual-route gene therapy treating Friedreich's ataxia, with first patient dosed in clinical trial.
Bakkt agrees to acquire Distributed Technologies Research in $150M stock deal. Clear Street analyst rates it a Buy with $39 target as stablecoin business expands.